"Medicare Expands Coverage to Include Wegovy for Heart Disease Risk"

Medicare will now cover Wegovy, a semaglutide medication, for patients at risk of heart disease, marking the first time a new blockbuster weight-loss drug will be covered by Medicare Part D plans. The move comes after the FDA expanded the approval of Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in people with cardiovascular disease and either overweight or obesity. This change could potentially lead to expanded coverage for other similar medications and may influence commercial insurance coverage as well.